Pfizer Inc. (NYSE:PFE) is considered one of the most undervalued blue chip stocks by hedge funds. Analyst Tim Anderson from Bank of America Securities maintained a Hold rating on Pfizer Inc. (NYSE:PFE) with a $27.00 price target, citing its breakthrough medicines as key to dividend stability.

The analyst’s rating for Pfizer Inc. (NYSE:PFE) is based on its future outlook and current market position. Pfizer Inc. (NYSE:PFE) faces competition from major pharmaceutical companies with its PD1-VEGF bispecific antibody, SSGJ-707, leading to uncertainties in clinical trial outcomes and cautious market dynamics.

Concerns about Pfizer Inc.’s (NYSE:PFE) long-term growth prospects were raised by Anderson due to competitive pressures and upcoming patent expirations. Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on advancing wellness and developing biopharmaceutical products worldwide.

While Pfizer Inc. (NYSE:PFE) shows investment potential, some AI stocks may offer greater upside potential with lower downside risk. For those seeking an undervalued AI stock poised to benefit from current trends, consider exploring the best short-term AI stock options.

Read more at Yahoo Finance: Bank of America Securities Maintains a Hold on Pfizer (PFE)